Home › Funds › Privium Fund Management B.V. › URGN

Privium Fund Management B.V. position in URGN

UROGEN PHARMA LTD · Health Care

Privium Fund Management B.V. reported holding 107,915 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 0.85% of its reported portfolio and ranking #25 among its reported holdings. Privium Fund Management B.V. has disclosed URGN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)107.92K sh
Reported value held$4.38M
Portfolio Weight0.85%
First reportedQ4 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Privium Fund Management B.V.'s URGN position evolved

Privium Fund Management B.V. first disclosed a stake in URGN in Q4 2024 at 27,691 shares (US$295K). The position peaked in Q2 2026 at 210,000 shares, worth US$7.7M. Across 8 filings, Privium Fund Management B.V. increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 107,915 shares valued at US$4.4M — a reduction of -102,085 shares quarter over quarter.. Notable position changes include a 289% increase in Q1 2025 (shares rose 24% over the following quarter), a 83% increase in Q3 2025 (shares rose 17% over the following quarter), a 49% trim in Q3 2026 (shares fell 36% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 27.69K $294.91K New
Q1 2025 107.62K $1.19M Add
Q2 2025 107.62K $1.40M Hold
Q3 2025 196.62K $3.92M Add
Q4 2025 214.62K $5.03M Add
Q1 2026 238.12K $4.28M Add
Q2 2026 210.00K $7.73M Reduce
Q3 2026 107.92K $4.38M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 45 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$89.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has Privium Fund Management B.V. held URGN?

Privium Fund Management B.V. has disclosed URGN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Privium Fund Management B.V.'s current position in URGN?

As of Q3 2026, Privium Fund Management B.V. holds 107.92K shares of URGN (UROGEN PHARMA LTD), valued at $4.38M, representing 0.85% of its reported portfolio and ranking #25.

Has Privium Fund Management B.V. been buying or selling URGN?

In the latest 13F filing (Q3 2026), Privium Fund Management B.V. reduced its position in URGN. The position peaked in Q2 2026 at 210.00K shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.